Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer

Einefors, Rickard; Kogler, Ulrika; Ellberg, Carolina; Olsson, Håkan

doi:10.1186/2193-1801-2-357

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, around 30% of breast cancers are ER-negative tumors, with a higher proportion in young breast cancer patients, and these tumors constitute a subgroup with relatively poorer prognosis and fewer treatment options 34 - 36 . Our enrichment results showed a common theme of immune response across the three different methods; these findings that are consistent with previous results highlighting the importance of immune pathways in ER-negative breast cancer 37 - 39 .…”

Section: Discussionsupporting

confidence: 92%

Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs

Anwar¹,

Wulaningsih²,

Watkins³

2017

Cancer Biology & Medicine

View full text Add to dashboard Cite

Objective:To determine the influence of the single nucleotide polymorphism (SNP) rs4245739 on the binding and expression of microRNAs and subsequent MDM4 expression and the correlation of these factors with clinical determinants of ER-negative breast cancers. Methods:FindTar and miRanda were used to detect the manner in which potential microRNAs are affected by the SNP rs4245739-flanking sequence. RNA sequencing data for ER-negative breast cancer from The Cancer Genome Atlas (TCGA) were used to compare the expression of miR-184, miR-191, miR-193a, miR-378, and MDM4 in different rs4245739 genotypes. Results:Comparison of ER-negative cancer patients with and without the expression of miR-191 as well as profile microRNAs (miR-184, miR-191, miR-193a and miR-378 altogether) can differentiate the expression of MDM4 among different rs4245739 genotypes. Although simple genotyping alone did not reveal significant clinical relationships, the combination of genotyping and microRNA profiles was able to significantly differentiate individuals with larger tumor size and lower number of involved lymph nodes (P < 0.05) in the risk group (A allele). Conclusions:We present two novel methods to analyze SNPs within 3′UTRs that use: (i) a single miRNA marker expression and (ii) an expression profile of miRNAs predicted to bind to the SNP region. We demonstrate that the application of these two methods, in particular the miRNA profile approach, permits detection of new molecular and clinical features related to the rs4245739 variant in ER-negative breast cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs

Anwar¹,

Wulaningsih²,

Watkins³

2017

Cancer Biology & Medicine

View full text Add to dashboard Cite

show abstract

“…To determine appropriate intervention in this group of patients, it is therefore essential to perform a comprehensive baseline evaluation of musculoskeletal complaints. Our results are in conflict with those by Einefors et al, who showed improved BC outcome in patients with ADs [23]. Indeed, among the 1705 BC patients included in that analysis, those with coexisting AD (125 patients) had a not significant trend towards better OS, adjusted for age at diagnosis and TN stage (HR 0.91; CI 0.72–1.14).…”

Section: Discussioncontrasting

confidence: 99%

Impact of autoimmune diseases on outcome of patients with early breast cancer

et al. 2016

View full text Add to dashboard Cite

Our aim was to analyze the impact of a concurrent autoimmune disease on outcome of patients with early breast cancer. We reviewed medical charts of patients with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. We categorized ADs as endocrine, rheumatic, systemic, neurological diseases and vasculitis. For each patient in the study group, we matched 2 patients. The events to determine overall survival (OS) and disease free survival (DFS) were identified from follow-up data. We identified 279 (1.62%) patients with early breast cancer and concurrent ADs. The median follow-up was 7.0 years. The 10-year OS rate was 86% (95% CI, 80% to 91%) in the study group and 90% (95% CI, 86% to 93%) for the control group (p = 0.011). In patients with ER positive/HER2 negative subtype a worse OS was observed in the study group when compared to the control group (p = 0.0046); this difference remained statistically significant when the analysis was restricted to breast cancer mortality (p = 0.045). The 10-year DFS rate was 69% (95% CI, 61% to 76%) in the study group and 72% (95% CI, 66% to 77%) for the control group (p = 0.22). Autoimmunity at diagnosis of early breast cancer is associated with worse survival.

show abstract

“…Prior studies have been inconsistent in demonstrating a definitive association between breast cancer aggressiveness and thyroid disease, particularly thyroid autoimmunity (14–16). One study reported that patients with any type of thyroid disease (including hyperthyroid patients) were more likely to have a greater degree of lymph node involvement, a larger primary tumor, and vascular invasion, but there was no significant correlation with breast cancer stage or ER or PR status (17).…”

Section: Introductionmentioning

confidence: 99%

Serum Thyrotropin Concentrations are not Predictive of Aggressive Breast Cancer Biology in Euthyroid Individuals

Villa

Yeh

et al. 2015

Endocrine Practice

View full text Add to dashboard Cite

Objective The potential influence of hypothyroidism on breast cancer remains incompletely understood. The objective of this study was to investigate the relationship between serum thyrotropin [thyroid-stimulating hormone (TSH)] concentration and markers of aggressive breast cancer biology, as defined by receptor expression profile, tumor grade, and American Joint Committee on Cancer (AJCC) stage characteristics. Methods This was a retrospective cohort study of patients from 2002–2014. All breast cancer patients who had complete receptor (estrogen receptor, ER; progesterone receptor, PR; and Her2/neu) and pre-diagnosis serum TSH data (n=437) were included. All patients had one of six receptor profiles: ER+ PR+ Her2/neu −, ER+ PR− Her2/neu−, ER+ PR+ Her2/neu+, ER+ PRHer2/ neu+, ER− PR− Her2/neu+, ER− PR− Her2/neu−. Log-transformed serum TSH concentrations were analyzed using multinomial and logistic regressions for a potential relationship with markers of breast cancer aggressiveness. Results Increasing serum TSH concentration was associated with a lower probability of having the receptor expression profile ER+ PR+ Her2/neu+ compared to patients with the ER+ PR+ Her2/neu− profile (OR=0.52, p=0.0045). No significant associations between other receptor expression profiles and serum TSH concentration were found. All time-weighted and unweighted median serum TSH concentrations were within normal limits. No significant associations between serum TSH concentration and tumor grade, overall AJCC stage, or tumor size (T), lymph node positivity (N), or presence of metastasis (M) were observed. Conclusions Serum TSH was not associated with markers of breast cancer aggressiveness in our cohort.

show abstract

Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer

Cited by 4 publications

References 25 publications

Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs

Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs

Impact of autoimmune diseases on outcome of patients with early breast cancer

Serum Thyrotropin Concentrations are not Predictive of Aggressive Breast Cancer Biology in Euthyroid Individuals

Contact Info

Product

Resources

About